1 |
Automatic image analysis methods for quantification of cerebral asymmetry : investigation of sexual dimorphism and schizophreniaBarrick, Thomas R. January 2004 (has links)
No description available.
|
2 |
Neuroimaging the ketamine model of schizophreniaLittlewood, Clare Louise January 2006 (has links)
No description available.
|
3 |
Genetic analysis of candidate genes for schizophrenia and its intermediate phenotypesDempster, Emma Louise January 2005 (has links)
No description available.
|
4 |
The neurocognitive correlates of normal and abnormal speech appraisalAllen, Paul January 2005 (has links)
No description available.
|
5 |
Susceptibility genes for schizophreniaKennedy, Nigel Iain January 2006 (has links)
No description available.
|
6 |
Investigations of gene expression in the pathogenesis of Schizophrenia : experimental and post-mortem studiesInkster, Becky January 2006 (has links)
No description available.
|
7 |
The role of serotonin in the aetiology of depressive symptoms in schizophreniaMulholland, C. C. January 2005 (has links)
No description available.
|
8 |
Obsessive and motor symptoms in Huntingdon's disease and schizophreniaDoherty, F. M. January 2006 (has links)
No description available.
|
9 |
Factors that influence a desire for social distancing from people with schizophrenia in an English general population sampleHay, Kelly Ann January 2007 (has links)
No description available.
|
10 |
Biomarkers of oxidative stress in models of schizophreniaYoung, Julie January 2007 (has links)
Background: Increasing evidence indicates that oxidative injury exists in schizophrenia. Although it may not be the main cause, oxidative damage has been suggested to contribute to the pathophysiology and may account for deteriorating course and poor outcome in schizophrenia. There is increasing interest in the neuroprotective efficacy of antioxidants in modulating such processes with at least one polyphenolic being tested as a prophylactic in Alzheimer's disease. Beneficial effects of adjunctive ω-3 (n-3 series) polyunsaturated fatty acids with combined intakes of vitamin C and E on both the positive and negative symptoms of schizophrenia have been reported. Robust in vitro systems are desirable, enabling a mechanistic investigation of the molecular mechanisms underpinning such effects and identification of further potentially efficacious nutraceuticals. Materials and Method: Comparative studies employing a lymphoblastoid cell line of schizophrenic origin, a neuroblastoma IMR-32 cell line and the lymphoma U937 cell line was undertaken. The cytoprotective effects of phenolic antioxidants and essential fatty acids in affording protection to cellular DNA, protein and lipids from an oxidative challenge were assessed in the three cell lines. In addition, two human studies were undertaken. The first study utilised the non-invasive technique of breath hydrocarbon analysis and the lipid peroxidation products in a population of schizophrenic patients were compared to a population of apparently healthy aged-matched control subjects, while the second study investigated possible differences in biomarkers of DNA, lipid and protein oxidation in schizophrenic and control subjects. Plasma vitamin C levels were also compared in both groups. Results and Conclusion: Cell Culture Studies: Pre-treatment of peripheral and neuronal cells with antioxidant or ω-3 fatty acids followed by an oxidative challenge significantly reduced the levels of DNA damage. Treatment with H₂O₂ alone and following pre-treatment with EPA or DHA had no effect on the levels of protein carbonyls in U937 cells, however, DHA supplementation did appear to reduce endogenous and H2O2-induced protein carbonylation. Marked differences in the uptake of fatty acids by the cell types were found and the IMR-32 cell line was most susceptible to the oxidant challenge. Hydroxytyrosol gave significant cytoprotection in all three cell lines and this possible neuroprotective efficacy warrants further investigation, both in vitro and in vivo. Treatment of the three cell lines with a high concentration of H2O2 for 30min or 4 hours did not induce a significant increase in MDA. U937 cells were supplemented for 24 hours with fatty acids followed by a 4 hour oxidative stress. Both EPA and DHA treatment appeared to reduce LOOH levels in the U937 cells but not significantly. Cytoplasmic PLA2 activity in the three human cell lines was examined and the basal level of cPLA2 activity was found to be comparable in the lymphoblastoid and IMR-32 cells but significantly lower than that measured in the U937 cells. Supplementation of the U937 cell line with EPA caused a significant decrease (p<0.05) in cPLA2 activity relative to the vehicle treated control but neither EPA nor DHA supplementation appeared to have any significant effect on either total PLA2 or cPLA2 activity in IMR-32 or lymphoblastoid cell lines. Abstract v Human Studies: No significant difference was found between the levels of ethane and pentane in the breath from the schizophrenic patients and control samples. In addition, no significant difference in the levels of plasma MDA between the two groups was detected. Ethane levels and MDA levels were higher in the male schizophrenic samples than in the female schizophrenic samples but the results were not statistically significant. The pentane levels were higher in the female schizophrenic samples when compared to the male schizophrenia samples but again, these were not significantly greater. Finally, results of study 2 revealed that cellular DNA damage and plasma protein carbonyl levels were increased in the schizophrenic group compared to control subjects but not significantly. However, DNA damage in lymphocytes from the male schizophrenic group was significantly higher than the female group. Biomarkers of lipid peroxidation and plasma vitamin C levels also revealed no significant difference between the two groups under investigation, although a significant elevation in plasma vitamin C was observed in the female control group when compared to the male groups. Treatment of cells with EPA, DHA and hydroxytyrosol to reduce levels of oxidative damage warrants further investigation. Ultimately, it is important to investigate a range of biomarkers to determine whether the measurement of oxidative damage to lipids, proteins and DNA has clinical significance. This will enable better understanding of the disease of interest and allow these biomarkers to become potentially useful clinical tools.
|
Page generated in 0.029 seconds